91 related articles for article (PubMed ID: 22929643)
1. Dyselectrolytemias after single dose of pamidronate administration.
Panday K; Kanth R
J Nepal Health Res Counc; 2012 Jan; 10(1):73-5. PubMed ID: 22929643
[TBL] [Abstract][Full Text] [Related]
2. Electrolyte disturbances and cardiac arrhythmias in a dog following pamidronate, calcitonin, and furosemide administration for hypercalcemia of malignancy.
Kadar E; Rush JE; Wetmore L; Chan DL
J Am Anim Hosp Assoc; 2004; 40(1):75-81. PubMed ID: 14736909
[TBL] [Abstract][Full Text] [Related]
3. Jaw osteonecrosis associated with intravenous bisphosphonate: is incidence reduced after adoption of dental preventive measures?
Fusco V; Baraldi A; Loidoris A; Ciuffreda L; Galassi C; Goia F; Scoletta M; Berrone S; Benech A; Ortega C; Berruti A;
J Oral Maxillofac Surg; 2009 Aug; 67(8):1775. PubMed ID: 19615599
[No Abstract] [Full Text] [Related]
4. Update on osteoporosis treatment. Should you stay on bisphosphonate drugs long-term?
Harv Womens Health Watch; 2012 Aug; 19(12):6. PubMed ID: 23033551
[No Abstract] [Full Text] [Related]
5. Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury.
Mechanick JI; Liu K; Nierman DM; Stein A
J Spinal Cord Med; 2006; 29(4):406-12. PubMed ID: 17044392
[TBL] [Abstract][Full Text] [Related]
6. A once-yearly IV bisphosphonate for osteoporosis.
Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
[No Abstract] [Full Text] [Related]
7. Bisphosphonate associated osteonecrosis of the jaws and endodontic treatment: two case reports.
Fugazzotto PA; Lightfoot S
J Mass Dent Soc; 2006; 55(2):5. PubMed ID: 16937899
[No Abstract] [Full Text] [Related]
8. Comment on the American Association of Oral and Maxillofacial Surgeons statement on bisphosphonates.
Zahrowski JJ
J Oral Maxillofac Surg; 2007 Jul; 65(7):1440-1. PubMed ID: 17577522
[No Abstract] [Full Text] [Related]
9. [New development in bisphosphonate treatment. Treatment with bisphosphonates for cancer-induced bone disease].
Abe M
Clin Calcium; 2009 Jan; 19(1):55-62. PubMed ID: 19122265
[TBL] [Abstract][Full Text] [Related]
10. [Jaw necrosis following treatment with biphosphonates--the dose is of crucial significance for the risk].
Langdahl BL; Hitz M; Melsen B; Pinholt EM
Ugeskr Laeger; 2009 Mar; 171(13):1103; author reply 1103. PubMed ID: 19330957
[No Abstract] [Full Text] [Related]
11. Management of bisphosphonate-induced osteonecrosis of the jaw.
Schilling J
Northwest Dent; 2008; 87(3):34-5, 37-8, 40. PubMed ID: 18663869
[TBL] [Abstract][Full Text] [Related]
12. A once-yearly IV bisphosphonate for osteoporosis.
Obstet Gynecol; 2008 May; 111(5):1208-9. PubMed ID: 18448761
[No Abstract] [Full Text] [Related]
13. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Mavrokokki T; Cheng A; Stein B; Goss A
J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
[TBL] [Abstract][Full Text] [Related]
14. By the way, doctor. Should I take an intravenous drug for osteoporosis?
Robb-Nicholson C
Harv Womens Health Watch; 2007 Jul; 14(11):8. PubMed ID: 17665505
[No Abstract] [Full Text] [Related]
15. Avascular necrosis of the proximal carpal row of the wrist. A possible complication of bisphosphonate administration.
Didden K; De Smet L; Vandenberghe L; Sciot R; Degreef I
Chir Main; 2012 Dec; 31(6):355-7. PubMed ID: 23177907
[TBL] [Abstract][Full Text] [Related]
16. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
Cheung MS; Glorieux FH; Rauch F
J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces.
Naik NH; Russo TA
Clin Infect Dis; 2009 Dec; 49(11):1729-32. PubMed ID: 19886792
[TBL] [Abstract][Full Text] [Related]
18. Sore mandible. Bisphosphonate-associated osteonecrosis.
Damm DD; Fantasia JE
Gen Dent; 2006; 54(5):370, 372. PubMed ID: 17004575
[No Abstract] [Full Text] [Related]
19. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
20. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
